Wunderlich G

References (1)

Title : Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease - Frolich_2019_Alzheimers.Res.Ther_11_18
Author(s) : Frolich L , Wunderlich G , Thamer C , Roehrle M , Garcia M, Jr. , Dubois B
Ref : Alzheimers Res Ther , 11 :18 , 2019
Abstract :
PubMedSearch : Frolich_2019_Alzheimers.Res.Ther_11_18
PubMedID: 30755255